Products

Clinical Trials

We recently initiated a Phase I clinical trial for XmAb™2513. This trial is designed to study the safety, tolerability, and pharmacokinetics in patients with Hodgkin lymphoma or anaplastic large cell lymphoma. We intend to enroll approximately 20-48 patients at four sites.

The following trial sites are currently participating:

  • The Ohio State University Comprehensive Cancer Center
  • Fox Chase Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • Rush Cancer Institute

For trial site information, please refer to www.clinicaltrials.gov or contact Rolondo Enoch, Xencor, at renoch@xencor.com or (626) 737-8072.

Additional information is available through the following organizations:

The Leukemia & Lymphoma Society

www.LLS.org/clinicaltrials or contact the Society's Information Resource Center at 800-955-4572 or via e-mail at infocenter@LLS.org to contact an Information Specialist (in English or Spanish).

The Lymphoma Research Foundation

www.lymphoma.org or contact the Society's Helpline at 800-500-9976 or via e-mail at helpline@lymphoma.org.